Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review

References

• ICS | overactive Bladder, Accessed: 21/ 8/ 2021. Available from: https://www.ics.org/committees/standardisation/terminologydiscussions/overactivebladder
   Google Scholar
• Eapen R, Radomski S. Review of the epidemiology of overactive bladder. Res Reports Urol. 2016 Jun 71. DOI:10.2147/RRU.S102441.
   PubMedGoogle Scholar
• Milsom I, Kaplan SA, Coyne KS, et al. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012 Jul;80:90–96.
   PubMed Web of Science ®Google Scholar
• Mitcheson D, Pinto CA, Frenkl T, et al. Once daily vibegron improves quality of life measures in patients with overactive bladder. Value Heal. 2018;21:S267–8.
   Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health‐related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011;59:1465–1470.
   PubMed Web of Science ®Google Scholar
• Hakimi S, Aminian E, Alizadeh, et al. Risk factors of overactive bladder syndrome and its relation to sexual function in menopausal women. Urol J. 2018 Feb;85:10–14.
   Google Scholar
• Hampel C, Wienhold D, Benken N, et al. Definition of overactive bladder and epidemiology of urinary incontinence. Urology. 1997 Dec;50:4–14.
   PubMed Web of Science ®Google Scholar
• Powell LC, Szabo SM, Walker D, et al. The economic burden of overactive bladder in the United States: a systematic literature review. Neurourol Urodyn. 2018 Apr;37:1241–1249.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014 Jan;33:17–30.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Mirabegron: a review in overactive bladder syndrome. Drugs. 2018;78:833–844.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol. 2013 Feb;63:283–295. Available from https://pubmed.ncbi.nlm.nih.gov/23182126/
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013 Jul;67:619–632.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Tyagi V, Chancellor M. Mirabegron: a safety review. Expert Opin Drug Saf. 2011 Mar;10:287–294.
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al., Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Spec Pharm JMCP. 2003. 9(1): 53–61.
   PubMedGoogle Scholar
• Unit Costs of Health and Social Care, 2010, Accessed: 21/ 8/ 2021, | PSSRU. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2010/
   Google Scholar
• Yamanishi Y, Yamanishi T, Tajima H, et al. Mirabegron or tolterodine for the treatment of overactive bladder in Japan: which drug is more cost-effective as the first-line treatment? Int J Urol. 2018;25:863–870.
   PubMed Web of Science ®Google Scholar
• Nazir J, Maman K, Nine M-E, et al. Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in the United Kingdom. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2015 Sep;18:783–790.
   PubMed Web of Science ®Google Scholar
• Murray B, Hessami SH, Gultyaev D, et al. Cost-effectiveness of overactive bladder treatments: from the US payer perspective. J Comp Eff Res. 2019 Jan;8:61–71.
   PubMed Web of Science ®Google Scholar
• Arlandis-Guzmán S, Brenes-Bermúdez F, Jiménez-Cidre MA, et al. Coste-efectividad de mirabegrón y los antimuscarínicos en pacientes con vejiga hiperactiva [Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder.]. Arch Esp Urol. 2018 Dec;71(10):809–824. Spanish. PMID: 30560796.
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004 May;13:437–452.
   PubMed Web of Science ®Google Scholar
• Wielage RC, Perk S, Campbell NL, et al. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health plan and medicare advantage perspectives. J Med Econ. 2016 Dec;19:1135–1143.
   PubMed Web of Science ®Google Scholar
• Aballéa S, Maman K, Thokagevistk K, et al. Cost-effectiveness of mirabegron compared with tolterodine extended-release for the treatment of adults with overactive bladder in the United Kingdom. Clin Drug Investig. 2015 Feb;35:83–93.
   PubMed Web of Science ®Google Scholar
• Zanghelini F, de Oliveira HA Jr, Silva TBC, et al. Cost-effectiveness analysis and budget impact: antimuscarinics and mirabegron for the treatment of patients with urge urinary incontinence, according to the Brazilian public health system perspective. Value Heal Reg Issues. 2020;23:85–92.
   PubMedGoogle Scholar
• Parise H, Espinosa R, Dea K, et al. Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in Colombia. Pharmacoecon Open. 2020 Mar 1;4:79–90. Available from.
   PubMed Web of Science ®Google Scholar
• Herschorn S, Vicente C, Nazir J, et al. Cost-effectiveness of mirabegron 50mg compared to tolterodine Er 4mg in the treatment of patients with overactive bladder in Canada. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014 Nov;17:A469.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013 Feb;63:283–295.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Thorpe A, Warner J, et al. The cost‐effectiveness of solifenacin vs fesoterodine, oxybutynin immediate‐release, propiverine, tolterodine extended‐release and tolterodine immediate‐release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2010;106:506–514.
   PubMed Web of Science ®Google Scholar
• Homepage, Accessed: 21/ 8/ 2021, BNF Publications, [Internet]. Available from: https://www.bnf.org/
   Google Scholar
• Conditions we treat Overactive bladder and urge incontinence| Nottingham Urology Group, Accessed: 21/ 8/ 2021. Available from: https://www.nottinghamurologygroup.co.uk/overactive-bladder-and-urge-incontinence
   Google Scholar
• Angulo JC, Sánchez-Ballester F, Peral C, et al. Cost-effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. Actas Urol Esp. 2016 Oct;40:513–522.
   PubMed Web of Science ®Google Scholar
• Griebling TL. Overactive bladder in elderly men: epidemiology, evaluation, clinical effects, and management. Curr Urol Rep. 2013;14:418–425.
   PubMed Web of Science ®Google Scholar
• Yeowell G, Smith P, Nazir J, et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ open. 2018 Nov 1;8(11):e021889.
   PubMed Web of Science ®Google Scholar
• Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care. 1990;6:93–103.
   PubMedGoogle Scholar
• Wathelet M, Duhem S, Vaiva G, et al. Factors associated with mental health disorders among university students in France confined during the COVID-19 pandemic. JAMA Network Open. Internet]. 2020 Oct 1;3:e2025591. Available from: /pmc/articles/PMC7584927/?report=abstract.
   PubMed Web of Science ®Google Scholar
• Joseph S, Maria SA, Peedicayil J. Drugs currently undergoing preclinical or clinical trials for the treatment of overactive bladder: a review. Curr Ther Res Clin Exp. 2022 Apr6;96:100669. PMID: 35494662; PMCID: PMC9052038.
   PubMed Web of Science ®Google Scholar
• Matza LS, Thompson CL, Krasnow J, et al. Test‐retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodynamics. 2005 May;24(3):215–225.
   PubMed Web of Science ®Google Scholar
• Piault E, Evans CJ, Espindle D, et al. Development and validation of the overactive bladder satisfaction (OAB‐S) questionnaire. Neurourol Urodyn. 2008 Mar;27(3):179–190.
   PubMed Web of Science ®Google Scholar
• Abrams P, Avery K, Gardener N, et al. The international consultation on incontinence modular questionnaire. J Urol. 2006 Mar;175(3):1063–1066. www.iciq.net
   PubMed Web of Science ®Google Scholar